Novel Combined Ato-C Treatment Synergistically Suppresses Proliferation of Bcr-Abl-Positive Leukemic Cells In Vitro and In Vivo

Chronic myelogenous leukemia (CML) accounts for 15-20% of all leukemias affecting adults. Despite recent advances in the development of specific Bcr-Abl tyrosine kinase inhibitors (TKIs), some CML patients suffer from relapse due to TKI resistance. Here, we assessed the efficacy of a novel combinatorial arsenic trioxide (ATO) and cisplatin (CDDP) treatment (Ato-C) in human Bcr-Abl-positive leukemic cells. Combination index analyses revealed that a synergistic interaction of ATO and CDDP elicits a wide range of effects in K562, KU-812, MEG-A2, and KCL-22 cells.

Source: Cancer Letters - June 23, 2018 Category: Cancer & Oncology Authors: Md Wahiduzzaman, Akinobu Ota, Sivasundaram Karnan, Ichiro Hanamura, Shohei Mizuno, Jo Kanasugi, Md Lutfur Rahman, Toshinori Hyodo, Hiroyuki Konishi, Shinobu Tsuzuki, Akiyoshi Takami, Yoshitaka Hosokawa Tags: Original Articles Source Type: research